Skip to main content
Ebola vaccine

Coronavirus and Ebola Show We Can’t Leave Vaccine Development to Big Pharma

Juliana Broad writes about the botched development of the Ebola vaccine, citing the work of The Democracy Collaborative’s Dana Brown on the necessity of public pharma.

Five years after an Ebola epidemic killed more than 11,000 people across West Africa, the U.S. Food and Drug Administration announced at the end of December 2019 that Merck, the behemoth, for-profit pharmaceutical company based in New Jersey, had received approval for an Ebola vaccine.

But this is hardly a success story. In fact, the saga behind the vaccine’s development sheds light on how involving private pharmaceutical companies may have obstructed the vaccine’s progress, profiting from publicly funded research only once the vaccine’s development proved to be lucrative business.

A new report, published in the Journal of Law and the Biosciences, details how the Ebola vaccine, Ervebo, was almost entirely researched and developed using public money, challenging the common assumption that only private, profit-driven companies are able to bring drugs to market.

Matthew Herder, one of the authors of the report, noted parallels between the Ebola response and the current coronavirus outbreak. “It seems fairly clear that the same approach — of patenting and licensing out to the private sector — is being relied upon by the public sector to advance vaccine development,” he told Truthout via email.

Herder emphasizes that their case study on Ebola cannot be generalized. Nonetheless, the authors raise a particularly urgent question as the U.S. struggles to marshal a response to a spreading coronavirus outbreak: Could the Ebola vaccine have been produced earlier, potentially saving thousands of lives, if researchers could have avoided the profit-driven trappings of private pharmaceutical companies?

Read the entire article at Truthout.

Publication date: 2020-03-09
Parent publication: Truthout
Publication URL: https://truthout.org/articles/coronavirus-and-ebola-show-we-cant-leave-vaccine-development-to-big-pharma/

More related work

Default Image

The Democracy Collaborative and The Democracy Collaborative Workers' Union agree to fair severance package for laid-off staff

TDC and union members have agreed to a package of protections that goes well beyond the baseline severance provisions for layoffs agreed to in TDC’s union contract.

read more
Default Image

HAN Anchoring Resilience: Aligning Supply Chains and Impact Purchasing for Community Health summit

Today the Healthcare Anchor Network (HAN) convened the Anchoring Resilience: Aligning Supply Chains and Impact Purchasing for Community Health summit to catalyze the conversation around how the healthcare sector could collaborate to more intentionally onshore and localize production of PPE and other important supplies with emphasis on equity, sustainability, and supply chain resilience. HAN released a white paper “Reimagining Personal Protective Equipment (PPE) Supply Chains” that calls for national leadership and healthcare sector collaboration to create PPE production capacity for American sourced and manufactured supplies.

read more
Default Image

Reimagining Personal Protective Equipment (PPE) Supply Chains

The Democracy Collaborative prepared a report, created for the Healthcare Anchor Network, which details the current status of the supply chain of PPE, the market shifts caused by COVID-19, and the potential solutions to ensure capacity within US health systems for the future.

read more